Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents-Reference-Cited by-同舟云学术

Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents

Published:2022-01-15 Issue:2 Volume:57 Page:90-98
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Seko Yuya,Moriguchi Michihisa,Takahashi Aya,Yamaguchi Kanji,Umemura Atsushi,Okuda Keiichiro,Kataoka Seita,Unozawa Hidemi,Kobayashi Kazufumi,Ogasawara Sadahisa,Sato Rui,Tsuchiya Satoshi,Watanabe Shunji,Morimoto Naoki,Iwai Kenji,Aramaki Takeshi,Kato Naoya,Itoh Yoshito

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

https://link.springer.com/content/pdf/10.1007/s00535-021-01837-5.pdf

Reference32 articles.

1. Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2016;2:16018.

2. Nagaoki Y, Aikata H, Miyaki D, et al. Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy. J Gastroenterol. 2011;46:799–808.

3. Tsuji K, Kurosaki M, Itakura J, et al. Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Gastroenterol. 2018;53:1142–50.

4. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649–59.

5. Kwo PY, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis. J Hepatol. 2017;67:263–71.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors;Scientific Reports;2024-07-16

2. Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication;Clinical and Molecular Hepatology;2024-07-01

3. Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study;JGH Open;2024-04

4. Well‐controlled viremia reduces the progression of hepatocellular carcinoma in chronic viral hepatitis patients treated with lenvatinib;The Kaohsiung Journal of Medical Sciences;2023-10-16

5. Nomogram to Predict the Long-Term Overall Survival of Early-Stage Hepatocellular Carcinoma after Radiofrequency Ablation;Cancers;2023-06-12